stella
beta
Home
/
Anaplastic Large Cell Lymphoma, ALK-Negative
/
Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin Cancers
View on ClinicalTrials.gov
Active, not recruiting
Back to Anaplastic Large Cell Lymphoma, ALK-Negative trials
Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin Cancers
Phase 2 — Testing in a larger group (up to a few hundred people) to further evaluate safety and begin to assess effectiveness.
Trial locations
(36 sites)
United States
Los Angeles General Medical Center, Los Angeles, California
USC / Norris Comprehensive Cancer Center, Los Angeles, California
UC Irvine Health/Chao Family Comprehensive Cancer Center, Orange, California
Keck Medical Center of USC Pasadena, Pasadena, California
University of California Davis Comprehensive Cancer Center, Sacramento, California
UCHealth University of Colorado Hospital, Aurora, Colorado
UM Sylvester Comprehensive Cancer Center at Aventura, Aventura, Florida
UM Sylvester Comprehensive Cancer Center at Coral Gables, Coral Gables, Florida
UM Sylvester Comprehensive Cancer Center at Deerfield Beach, Deerfield Beach, Florida
University of Miami Miller School of Medicine-Sylvester Cancer Center, Miami, Florida
UM Sylvester Comprehensive Cancer Center at Kendall, Miami, Florida
UM Sylvester Comprehensive Cancer Center at Plantation, Plantation, Florida
Northwestern University, Chicago, Illinois
University of Kansas Clinical Research Center, Fairway, Kansas
University of Kansas Cancer Center-Overland Park, Overland Park, Kansas
University of Kansas Hospital-Indian Creek Campus, Overland Park, Kansas
University of Kansas Hospital-Westwood Cancer Center, Westwood, Kansas
Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore, Maryland
Massachusetts General Hospital Cancer Center, Boston, Massachusetts
Dana-Farber Cancer Institute, Boston, Massachusetts
Siteman Cancer Center at Saint Peters Hospital, City of Saint Peters, Missouri
Siteman Cancer Center at West County Hospital, Creve Coeur, Missouri
University of Kansas Cancer Center - North, Kansas City, Missouri
University of Kansas Cancer Center - Lee's Summit, Lee's Summit, Missouri
University of Kansas Cancer Center at North Kansas City Hospital, North Kansas City, Missouri
Washington University School of Medicine, St Louis, Missouri
Siteman Cancer Center-South County, St Louis, Missouri
University of Nebraska Medical Center, Omaha, Nebraska
Dartmouth Hitchcock Medical Center/Dartmouth Cancer Center, Lebanon, New Hampshire
Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey
Roswell Park Cancer Institute, Buffalo, New York
Laura and Isaac Perlmutter Cancer Center at NYU Langone, New York, New York
UNC Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina
University of Pittsburgh Cancer Institute (UPCI), Pittsburgh, Pennsylvania
Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center, Houston, Texas
Huntsman Cancer Institute/University of Utah, Salt Lake City, Utah
Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin Cancers — Stella